Inventor · disambiguated record
Colin Philip Leslie
Also filed as: LESLIE COLIN · LESLIE COLIN P · LESLIE COLIN PHILIP
15 granted patents·10 pending applications·69 citations·filing 2003–2024
90Inventor score
Files withDENALI THERAPEUTICS INC9GLAXO GROUP LTD8ANNEXON INC2BENTLEY JONATHAN2BARTON NICHOLAS PAUL1
Top patents by PatentIndex Score
25 records- 0197US9815850B2Compounds, compositions and methodsDENALI THERAPEUTICS INC·Filed 2017·Granted Nov 14, 2017·36 cites·41 claims
- 0286US10604535B2Compounds, compositions and methodsDENALI THERAPEUTICS INC·Filed 2018·Granted Mar 31, 2020·3 cites·18 claims
- 0386US10131676B2Compounds, compositions and methodsDENALI THERAPEUTICS INC·Filed 2017·Granted Nov 20, 2018·3 cites·33 claims
- 0484US11814404B2Inhibitors of complement factors and uses thereofANNEXON INC·Filed 2021·Granted Nov 14, 2023·2 cites·48 claims
- 0583US11203600B2Kinase inhibitors and uses thereofDENALI THERAPEUTICS INC·Filed 2019·Granted Dec 21, 2021·2 cites·24 claims
- 0683US7459456B2Quinoline and quinazoline derivatives having affinity for 5HT1-type receptorsGLAXO GROUP LTD·Filed 2007·Granted Dec 2, 2008·7 cites·12 claims
- 0783US7279481B2Quinoline and quinazoline derivatives having affinity for 5HT1-type receptorsGLAXO GROUP LTD·Filed 2004·Granted Oct 9, 2007·15 cites·4 claims
- 0880US2025011338A1Kinase Inhibitors and Uses ThereofDENALI THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0972US7592346B2Quinoline and quinazoline derivatives having affinity for 5HT1-type receptorsGLAXO GROUP LTD·Filed 2008·Granted Sep 22, 2009·1 cites·25 claims
- 1069US12129263B2Kinase inhibitors and uses thereofDENALI THERAPEUTICS INC·Filed 2021·Granted Oct 29, 2024·0 cites·19 claims
- 1167US11851433B2Compounds, compositions and methodsDENALI THERAPEUTICS INC·Filed 2021·Granted Dec 26, 2023·0 cites·17 claims
- 1266US12509474B2Inhibitors of complement factors and uses thereofANNEXON INC·Filed 2023·Granted Dec 30, 2025·0 cites·36 claims
- 1366US7732600B2Quinoline and quinazoline derivatives having affinity for 5HT1-type receptorsGLAXO GROUP LTD·Filed 2009·Granted Jun 8, 2010·0 cites·4 claims
- 1455US11174262B2Compounds, compositions and methodsDENALI THERAPEUTICS INC·Filed 2019·Granted Nov 16, 2021·0 cites·16 claims
- 1554US2009076274A1Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disordersGLAXO GROUP LTD·Filed 2008·Application pending·0 cites
- 1652US2009042897A1Chemical CompoundsGLAXO GROUP LTD·Filed 2008·Application pending·0 cites
- 1751US2010204273A1Quinoline and Quinazoline Derivatives Having Affinity for 5HT1-Type ReceptorsGLAXO GROUP LTD·Filed 2010·Application pending·0 cites
- 1847US2010286151A11-OXA-3-Azaspiro[4,5]Decan--2-One Derivatives For The Treatment Of Eating DisordersBENTLEY JONATHAN·Filed 2008·Application pending·0 cites
- 1944US2006264429A1Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disordersBERTANI BARBARA·Filed 2003·Application pending·0 cites
- 2041US2010197699A1I-OXA-3-Azaspiro (4.5) Decan-2-One And 1-OXA-3, 8-Diazaspiro (4.5) Decan-2-One Derivatives For The Treatment of Eating DisordersGLAXO GROUP LTD·Filed 2008·Application pending·0 cites
- 2140US10709692B2Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (RIPK1)DENALI THERAPEUTICS INC·Filed 2016·Granted Jul 14, 2020·0 cites·28 claims
- 2240US2010216821A1Benzimidazoles With A Hetero Spiro-Decane Residue As NPY-Y5 AntagonistsBARTON NICHOLAS PAUL·Filed 2008·Application pending·0 cites
- 2338US2009203705A1Spiro Compounds As NPY Y5 Receptor AntagonistsBIAGETTI MATTEO·Filed 2009·Application pending·0 cites
- 2436US2012022056A1Fused tricyclic derivatives for the treatment of psychotic disordersBENTLEY JONATHAN·Filed 2005·Application pending·0 cites
- 2529US9920053B2N-(hetero)aryl-substituted heteroyclic derivatives useful for the treatment of diseases or conditions related to the central nervous systemCHRONOS THERAPEUTICS LTD·Filed 2015·Granted Mar 20, 2018·0 cites·21 claims
Join the waitlist — get patent alerts
Get an alert when Colin Philip Leslie files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →